Search results

1 – 10 of over 10000
Open Access
Article
Publication date: 26 March 2018

Betty Steenkamer, Caroline Baan, Kim Putters, Hans van Oers and Hanneke Drewes

A range of strategies to improve pharmaceutical care has been implemented by population health management (PHM) initiatives. However, which strategies generate the desired…

2497

Abstract

Purpose

A range of strategies to improve pharmaceutical care has been implemented by population health management (PHM) initiatives. However, which strategies generate the desired outcomes is largely unknown. The purpose of this paper is to identify guiding principles underlying collaborative strategies to improve pharmaceutical care and the contextual factors and mechanisms through which these principles operate.

Design/methodology/approach

The evaluation was informed by a realist methodology examining the links between PHM strategies, their outcomes and the contexts and mechanisms by which these strategies operate. Guiding principles were identified by grouping context-specific strategies with specific outcomes.

Findings

In total, ten guiding principles were identified: create agreement and commitment based on a long-term vision; foster cooperation and representation at the board level; use layered governance structures; create awareness at all levels; enable interpersonal links at all levels; create learning environments; organize shared responsibility; adjust financial strategies to market contexts; organize mutual gains; and align regional agreements with national policies and regulations. Contextual factors such as shared savings influenced the effectiveness of the guiding principles. Mechanisms by which these guiding principles operate were, for instance, fostering trust and creating a shared sense of the problem.

Practical implications

The guiding principles highlight how collaboration can be stimulated to improve pharmaceutical care while taking into account local constraints and possibilities. The interdependency of these principles necessitates effectuating them together in order to realize the best possible improvements and outcomes.

Originality/value

This is the first study using a realist approach to understand the guiding principles underlying collaboration to improve pharmaceutical care.

Details

Journal of Health Organization and Management, vol. 32 no. 2
Type: Research Article
ISSN: 1477-7266

Keywords

Article
Publication date: 1 December 2001

Waleed M. S. Al‐Shaqha and Mohamed Zairi

Institutional pharmaceutical services have widely evolved over the past 20‐30 years. Hospital pharmacy practice has changed from a profession concerned chiefly with the bulk…

3635

Abstract

Institutional pharmaceutical services have widely evolved over the past 20‐30 years. Hospital pharmacy practice has changed from a profession concerned chiefly with the bulk preparation and distribution of drug products to one centred on ensuring optimal drug therapy. Whereas hospital pharmacists were charged with maintaining large drug stock on nursing units, many of them now provide individualised patient therapies. The practice of hospital pharmacy has therefore become one encompassing all aspects of drug therapy, from the procurement of drugs and drug delivery devices, their preparation and distribution, to their most appropriate selection and use for each patient. Hospital pharmacy services have traditionally had little involvement at the key stages in patients’ hospital care. This leads to the conclusion that the model of clinical pharmacy practice adopted by many pharmacy department hospitals is no longer appropriate for the demands of today’s health‐care services. Reviews many new models proposed for clinical pharmacy practice including an integrated model for providing a pharmaceutical care management approach in the health‐care system. This model is a response to the failures of traditional drug therapy. It is primarily an idea about how health professionals and patient should integrate their work to obtain outcomes important to patients and clinicians.

Details

International Journal of Health Care Quality Assurance, vol. 14 no. 7
Type: Research Article
ISSN: 0952-6862

Keywords

Article
Publication date: 1 December 1998

Waleed M. Al‐Shakhaa and Mohammed Zairi

The success ofIn recent years, there has been significant interest in the application of continuous quality improvement (CQI) and total quality management (TQM), and…

2222

Abstract

The success ofIn recent years, there has been significant interest in the application of continuous quality improvement (CQI) and total quality management (TQM), and patient‐focused care (PFC) in health care organisations around the globe. The hospital industry has substantially embraced the concepts of CQI and TQM with the belief that these concepts and programmes will lead to an improvement in both the quality and efficiency with which health services are delivered. The objective of this article is to achieve better outcomes in health care services with fewer resources by studying the implementation of patient‐focused care in the health care provision context and particularly in the area of pharmaceutical care management as an integrated process in the delivery of health care in a hospital setting. The changes in health care provision have in many instances meant that the provision of pharmaceutical services needed re‐assessing.

Details

Health Manpower Management, vol. 24 no. 6
Type: Research Article
ISSN: 0955-2065

Keywords

Article
Publication date: 1 February 2001

Waleed M.S. Al‐Shaqha and Mohamed Zairi

Pharmaceutical care has caused considerable attention in the pharmacy literature, because this concept alters the care and services that pharmacists provide to the public. In the…

2257

Abstract

Pharmaceutical care has caused considerable attention in the pharmacy literature, because this concept alters the care and services that pharmacists provide to the public. In the pharmaceutical care concept, pharmacists must ultimately accept their responsibility not only to dispense drugs but also to identify, correct and prevent drug‐related problems. Pharmaceutical care represents a significant transition in the profession of pharmacy, where the primary focus is the patient and outcomes of care rather than the distribution of drug products. This article evaluates the concept of pharmaceutical care as a standard of quality care for many hospital pharmacy practices. As pharmacy directors accept this concept and pharmacists begin to provide pharmaceutical care, it is important to elaborate the concept further.

Details

Managing Service Quality: An International Journal, vol. 11 no. 1
Type: Research Article
ISSN: 0960-4529

Keywords

Article
Publication date: 29 June 2018

Chris I. Enyinda, Alphonso O. Ogbuehi and Chris H. Mbah

The purpose of this paper is to identify key social medial channels which pharmaceutical firms need to consider when desiring to understand consumer behavior, build, maintain and…

3216

Abstract

Purpose

The purpose of this paper is to identify key social medial channels which pharmaceutical firms need to consider when desiring to understand consumer behavior, build, maintain and proactively manage relationships. Also, it proposes the application of analytic hierarchy process (AHP) sensitivity analysis algorithm to test the stability or robustness of the priority ranking. Specifically, this paper leverages performance sensitivity analysis to evaluate how small changes (perturbation) in the major objectives of the pharmaceutical relationship marketing (PRM) tactics within the social media environment will influence the ranking of the alternative course of actions.

Design/methodology/approach

This paper used AHP-based questionnaire survey to evaluate the relative importance of factors accounting for PRM and the impact of social media channels. The major objectives and the alternative strategies used were from literature reviewed. Interviews with senior managers were insightful and helpful in the wording, content and format of the questionnaire.

Findings

Customer engagement is the most important PRM tactic, followed by communication and trust. The performance sensitivity analysis carried out on the PRM tactics showed that the ranking associated with social media channel options remained robust or insensitive to small perturbations.

Research limitations/implications

The data procured for this paper were based on one focal pharmaceutical firm. Convincing the same to grant an interview and late responding to the questionnaire was a great challenge.

Practical implications

Social media impact on pharmaceutical marketing relationship is important for pharmaceutical marketers. PRM bodes well with the social media environment. Pharmaceutical industry can build and maintain relationships with consumers through social media. Firms that leverage social media to enhance their PRM tactics will be viewed favorably in terms of trust, transparency, openness and honesty. The results provide pharmaceutical marketing managers with insightful and valuable information with respect to the role or social media impact on the PRM. The AHP model, objectives and their relative importance provide valuable information for managers on how to monitor the values that matters to customers the most.

Originality/value

This paper is one of the very few on the PRM and perhaps the first that examines social impact leveraging the AHP model. In addition, this paper contributes to the relationship marketing literature by leveraging a multi-criteria decision-making algorithm to prioritize the most important factors accounting for the PRM strategies.

Details

International Journal of Pharmaceutical and Healthcare Marketing, vol. 12 no. 2
Type: Research Article
ISSN: 1750-6123

Keywords

Article
Publication date: 1 September 2000

Waleed M.S. Al‐Shaqha and Mohamed Zairi

As healthcare reform takes shape, many challenges face hospital pharmacists. An opportunity exists to combine the principles of patient‐focused care and pharmaceutical care to…

1873

Abstract

As healthcare reform takes shape, many challenges face hospital pharmacists. An opportunity exists to combine the principles of patient‐focused care and pharmaceutical care to redesign the role of pharmacy. To achieve this objective, pharmacy departments should adopt business concepts such as process re‐engineering. Process re‐engineering is a change management tool which aims to produce dramatic improvement in performance measures by re‐designing the process. The goal of restructuring is to increase the amount of time pharmacists spend providing pharmaceutical care to patients. The pharmaceutical care concept is a method of delivering pharmaceutical care services that match individual patient needs with the services provided. This article describes many hospital pharmacy department transitions to a patient focused care environment by adopting the patient focused care concept and the process re‐engineering to improve the quality of patient care through systems improvement.

Details

International Journal of Health Care Quality Assurance, vol. 13 no. 5
Type: Research Article
ISSN: 0952-6862

Keywords

Article
Publication date: 8 November 2022

Arif Ibne Asad and Boris Popesko

The COVID-19 pandemic creates inefficiencies in the health-care system by having devastating consequences. It has demonstrated how inefficiencies in the health system can have a…

Abstract

Purpose

The COVID-19 pandemic creates inefficiencies in the health-care system by having devastating consequences. It has demonstrated how inefficiencies in the health system can have a significant impact on social cohesion, economic growth and public confidence in government. The main purpose of this study is to explore the contemporary challenges faced by the pharmaceutical industry in Europe.

Design/methodology/approach

This study used a systematic literature review method and adopted inclusion and exclusion criteria after constructive reviews of articles from Web of Science and Scopus databases along with the ranked journals in the Chartered Association of Business Schools to search the following key terms “challenges in the European pharmaceutical industry” during the period from 2011 to 2022. The terms are set to be searched in the publications’ titles, abstracts and keywords.

Findings

This study reviewed 57 papers, and the systematic review revealed the vulnerability of the European pharmaceutical industry, such as the default patent system, ineffective research and development, debate on the role of alliances, low level of expertise in the European health-care system, pharmaceutical supply chain management and other issues.

Research limitations/implications

This study suggests that future research may explore the challenges of multisectoral and cross-country perspectives to get a better understanding, and for the long-term sustainability of public pharmaceutical spending, new models of enhancing research investments are needed, and Europe can still play a leading role in its tradition structure within capturing innovative ideas.

Practical implications

It provides new useful insights to policymakers, global leaders and managers to devise policies to achieve a performance-oriented culture in their institutions and firms.

Social implications

The pharmaceutical sector has recognized the influence of social determinants of health. It moves toward sustained sound health of people to have a flourishing pharmaceutical sector.

Originality/value

There is an insufficient study on the contemporary challenges of the European pharmaceutical industry. This study presents the argument that earlier studies ignored the contemporary issues facing the European pharmaceutical industry from a comprehensive and wider angle. In addition, the COVID-19 pandemic is a recent occurrence, and it causes inefficiency in the health-care sector, where the pharmaceutical industry plays a crucial role; importantly, this topic is emerging and underresearched in the existing literature. There is also a lack of systematic literature review studies in this field.

Details

Measuring Business Excellence, vol. 27 no. 2
Type: Research Article
ISSN: 1368-3047

Keywords

Article
Publication date: 22 December 2021

Suparak Suriyankietkaew and Pavinee Kungwanpongpun

This empirical study aims to identify the essential strategic leadership and management factors underlying sustainability in healthcare. It also examines which factors drive…

1138

Abstract

Purpose

This empirical study aims to identify the essential strategic leadership and management factors underlying sustainability in healthcare. It also examines which factors drive sustainability performance outcomes (SPO) in health-care organizations, an analysis lacking to date. It provides a strategic leadership and management perspective toward sustainable healthcare, responding to the United Nations Sustainable Development Goals.

Design/methodology/approach

The investigation adopted Sustainable Leadership as its research framework. Using a cross-sectional survey, 543 employees working in health-care and pharmaceutical companies in Thailand voluntarily provided responses. Factor analyses and structural equation modeling were employed.

Findings

The results revealed an emergent research model and identified 20 unidimensional strategic leadership and management factors toward sustainability in healthcare. The findings indicate significant positive effects on SPO in health-care organizations. Significant factors include human resource management/development, ethics, quality, environment and social responsibility, and stakeholder considerations.

Research limitations/implications

The study was conducted in one country. Future studies should examine these relationships in diverse contexts. In practice, health-care firms should foster significant strategic leadership and management practices to improve performance outcomes for sustainability in healthcare.

Originality/value

This paper is the first empirical, multidisciplinary study with a focus on strategic leadership, health-care management and organizational sustainability. It identifies a proxy for measuring the effects of essential strategic leadership and managerial factors for sustainability in pharmaceutical health-care companies. It advances our currently limited knowledge and provides managerial implications for improving performance outcomes toward sustainable healthcare.

Details

Journal of Health Organization and Management, vol. 36 no. 4
Type: Research Article
ISSN: 1477-7266

Keywords

Article
Publication date: 11 November 2013

Nina Preschitschek, Helen Niemann, Jens Leker and Martin G. Moehrle

The convergence of industries exposes the involved firms to various challenges. In such a setting, a firm's response time becomes key to its future success. Hence, different

3245

Abstract

Purpose

The convergence of industries exposes the involved firms to various challenges. In such a setting, a firm's response time becomes key to its future success. Hence, different approaches to anticipating convergence have been developed in the recent past. So far, especially IPC co-classification patent analyses have been successfully applied in different industry settings to anticipate convergence on a broader industry/technology level. Here, the aim is to develop a concept to anticipate convergence even in small samples, simultaneously providing more detailed information on its origin and direction.

Design/methodology/approach

The authors assigned 326 US-patents on phytosterols to four different technological fields and measured the semantic similarity of the patents from the different technological fields. Finally, they compared these results to those of an IPC co-classification analysis of the same patent sample.

Findings

An increasing semantic similarity of food and pharmaceutical patents and personal care and pharmaceutical patents over time could be regarded as an indicator of convergence. The IPC co-classification analyses proved to be unsuitable for finding evidence for convergence here.

Originality/value

Semantic analyses provide the opportunity to analyze convergence processes in greater detail, even if only limited data are available. However, IPC co-classification analyses are still relevant in analyzing large amounts of data. The appropriateness of the semantic similarity approach requires verification, e.g. by applying it to other convergence settings.

Article
Publication date: 11 September 2007

Joshua Cohen

The purpose of this paper is to provide commentary on the state of affairs regarding implementation of Dutch health insurance reform, focusing on whether such reform is conducive…

859

Abstract

Purpose

The purpose of this paper is to provide commentary on the state of affairs regarding implementation of Dutch health insurance reform, focusing on whether such reform is conducive to pharmaceutical innovation.

Design/methodology/approach

The general characteristics of the Dutch healthcare system is outlined, together with a brief synopsis of the 2006 health insurance reform initiative. This is followed by a description of the four market intervention mechanisms and their implications for pharmaceutical innovation. Finally, these implications and the potential for policy transfer to other European countries are discussed.

Findings

The new Dutch health insurance system represents a novel approach that closely follows Enthoven's managed competition model. Certain features of the new system are conducive to pharmaceutical innovation. These positive features include more flexibility on the part of private insurers to deviate from the national formulary, speedier reimbursement appraisals, and more earmarked funding for certain highly innovative pharmaceutical products. Other features, however, appear detrimental to drug innovation. These include direct price controls, reference pricing, and the still highly centralized nature of decision making with respect to drug reimbursement. On the whole, one could say that, despite many challenges, Dutch health insurance reform is a step in the right direction that may prove to be a boon to biopharmaceutical innovation if further steps are taken to remove obstacles.

Research limitations/implications

It is premature to draw firm conclusions on whether Dutch health insurance reform is conducive to pharmaceutical innovation. The new system is at an early stage in its evolution. Further, one should be cautious about the extent to which lessons can be drawn from the new Dutch system for other European countries, given the limited size of the Dutch biopharmaceutical industry relative to some of its European neighbors.

Originality/value

While much is known about how changes in the drug regulatory framework impact pharmaceutical innovation, very little is known about how changes in health care insurance impact pharmaceutical innovation. This paper aims to fill that void by examining the impact of the new Dutch health insurance system on drug innovation.

Details

International Journal of Pharmaceutical and Healthcare Marketing, vol. 1 no. 3
Type: Research Article
ISSN: 1750-6123

Keywords

1 – 10 of over 10000